Literature DB >> 26135440

Be prepared: Europe needs Ebola outbreak consortium.

Alimuddin Zumla1, David Heymann2, Giuseppe Ippolito3.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26135440     DOI： 10.1038/523035b

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  2 in total

1.  Ebola: an open letter to European governments.

Authors:  Jose M Martin-Moreno; Walter Ricciardi; Vesna Bjegovic-Mikanovic; Peggy Maguire; Martin McKee
Journal:  Lancet       Date:  2014-09-25       Impact factor: 79.321

Review 2.  Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?

Authors:  Simone Lanini; Alimuddin Zumla; John P A Ioannidis; Antonino Di Caro; Sanjeev Krishna; Lawrence Gostin; Enrico Girardi; Michel Pletschette; Gino Strada; Aldo Baritussio; Gina Portella; Giovanni Apolone; Silvio Cavuto; Roberto Satolli; Peter Kremsner; Francesco Vairo; Giuseppe Ippolito
Journal:  Lancet Infect Dis       Date:  2015-04-14       Impact factor: 25.071
  2 in total
  3 in total

1.  Preface - Emerging Viruses: From Early Detection to Intervention.

Authors:  Giuseppe Ippolito; Giovanni Rezza
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

2.  Taking forward a 'One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential.

Authors:  Alimuddin Zumla; Osman Dar; Richard Kock; Matthew Muturi; Francine Ntoumi; Pontiano Kaleebu; Macete Eusebio; Sayoki Mfinanga; Matthew Bates; Peter Mwaba; Rashid Ansumana; Mishal Khan; Abdulaziz N Alagaili; Matthew Cotten; Esam I Azhar; Markus Maeurer; Giuseppe Ippolito; Eskild Petersen
Journal:  Int J Infect Dis       Date:  2016-06-15       Impact factor: 3.623

3.  The Middle East Respiratory Syndrome Coronavirus - A Continuing Risk to Global Health Security.

Authors:  Esam I Azhar; Simone Lanini; Giuseppe Ippolito; Alimuddin Zumla
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.